logo
Science Portal
Copyright © Médecins Sans Frontières
v2.1.5153.produseast1
About MSF Science Portal
About
Contact Us
Frequently Asked Questions (FAQs)
Privacy Policy
Terms of Use
Copyright © Médecins Sans Frontières
v2.1.5153.produseast1
Showing 1 - 8 of 8 Items
Showing 1 - 8 of 8 Items
Sort By: Relevance
  • Newest to oldest
  • Oldest to newest
  • Relevance
Journal Article
|
Research

rVSV-ZEBOV vaccination in people with pre-existing immunity to Ebolavirus: an open-label safety and immunogenicity study in Guinean communities affected by Ebola virus disease (l’essai proches)

Watson CH, Gsell PS, Hall Y, Camacho A, Riveros X,  et al.
2024-11-07 • BMC Medicine
2024-11-07 • BMC Medicine

BACKGROUND

Zaire Ebolavirus disease (EVD) outbreaks can be controlled using rVSV-ZEBOV vaccination and other public health measures. People in high-risk areas m...

Journal Article
|
Protocol

A prospective, multi-site, cohort study to estimate incidence of infection and disease due to Lassa fever virus in West African countries (the Enable Lassa research programme)–Study protocol

Penfold S, Adegnika AA, Asogun D, Ayodeji O, Azuogu BN,  et al.
2023-03-30 • PLOS One
2023-03-30 • PLOS One
BACKGROUND
Lassa fever (LF), a haemorrhagic illness caused by the Lassa fever virus (LASV), is endemic in West Africa and causes 5000 fatalities every year. The true prevalence and i...
Journal Article
|
Letter

Temporal and spatial analysis of the 2014-2015 Ebola virus outbreak in West Africa

Carroll MW, Matthews DA, Hiscox JA, Elmore MJ, Pollakis G,  et al.
2015-06-17 • Nature
2015-06-17 • Nature
West Africa is currently witnessing the most extensive Ebola virus (EBOV) outbreak so far recorded. Until now, there have been 27,013 reported cases and 11,134 deaths. The origin of the ...
Journal Article
|
Research

Experimental Treatment with Favipiravir for Ebola Virus Disease (the JIKI Trial): A Historically Controlled, Single-Arm Proof-of-Concept Trial in Guinea

Sissoko D, Laouenan C, Folkesson E, M’Lebing A, Beavogui A,  et al.
2016-03-01 • PLOS Medicine
2016-03-01 • PLOS Medicine
Ebola virus disease (EVD) is a highly lethal condition for which no specific treatment has proven efficacy. In September 2014, while the Ebola outbreak was at its peak, the World Health ...
Journal Article
|
Letter

Detection of Marburg virus disease in Guinea

Koundouno FR, Kafetzopoulou LE, Faye M, Renevey A, Soropogui B,  et al.
2022-06-30 • New England Journal of Medicine
2022-06-30 • New England Journal of Medicine
Journal Article
|
Research

Unique human immune signature of Ebola Virus Disease in Guinea

Ruibal P, Oestereich L, Ludtke A, Becker-Ziaja B, Wozniak DM,  et al.
2016-05-04 • Nature
2016-05-04 • Nature
Despite the magnitude of the Ebola virus disease (EVD) outbreak in West Africa, there is still a fundamental lack of knowledge about the pathophysiology of EVD. In particular, very littl...
Journal Article
|
Research

Transcriptomic Signatures Differentiate Survival from Fatal Outcomes in Humans Infected with Ebola Virus

Liu X, Speranza E, Munoz-Fontela C, Haldenby S, Rickett NY,  et al.
2017-01-19 • Genome Biology
2017-01-19 • Genome Biology
In 2014, Western Africa experienced an unanticipated explosion of Ebola virus infections. What distinguishes fatal from non-fatal outcomes remains largely unknown, yet is key to optimisi...
Journal Article
|
Research

Efficacy and Effectiveness of an rVSV-Vectored Vaccine in Preventing Ebola Virus Disease: Final Results from the Guinea Ring Vaccination, Open-Label, Cluster-Randomised Trial (Ebola Ça Suffit!)

Henao-Restrepo AM, Camacho A, Longini I, Watson CH, Edmunds WJ,  et al.
2017-02-01 • Lancet
2017-02-01 • Lancet
BACKGROUND
rVSV-ZEBOV is a recombinant, replication competent vesicular stomatitis virus-based candidate vaccine expressing a surface glycoprotein of Zaire Ebolavirus. We tested the ...